Sanofi

This study tests a new vaccine (PCV21) that protects against 21 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. About 2,360 healthy infants will receive either the new vaccine or a current one at 2, 4, 6, and 12-15 months old. The main g…

This study tests a new vaccine (PCV21) in healthy infants to see if it safely helps their bodies build defenses against 21 types of pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. About 1,092 babies will receive either the new vaccine or a …

This study tests a new vaccine designed to protect against the Omicron JN.1 variant of COVID-19. About 120 adults aged 65 and older, or those aged 12-64 with health conditions that raise their risk, will receive one shot. Researchers will check how well the vaccine boosts immunit…

This study tests a new vaccine designed to protect against four types of meningococcal bacteria that can cause meningitis and bloodstream infections. About 1,600 healthy children and teens aged 2 to 17 in China will receive either the new vaccine or a currently approved one. Rese…

This study looks at the safety of the Tdap5 vaccine (Adacel) given to pregnant women after 27 weeks of pregnancy. Researchers will compare over 365,000 vaccinated and unvaccinated mothers and their babies to see if there are any differences in pregnancy outcomes like preterm birt…

This study tests whether a new 21-valent pneumococcal vaccine is safe and helps build immunity in healthy infants and toddlers when given after one or more doses of a current 20-valent vaccine. About 580 babies will receive different vaccine schedules starting at 2 months old. Th…

This study tests a new mRNA vaccine designed to protect against a potential pandemic flu (H5N1). About 720 healthy adults aged 18 and older will receive either a high, medium, or low dose of the vaccine or a placebo. The goal is to see if the vaccine is safe and triggers a strong…

This study looks at the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive the drug for up to 5 years, with regular check-ups to monitor side effects and skin improv…

This study tests an experimental drug called SAR441344 in 129 adults with relapsing multiple sclerosis. The drug blocks a protein (CD40L) to reduce new active brain lesions seen on MRI. Participants receive either the drug or a placebo for several weeks. The goal is to see if the…

This study tests if dupilumab can help people with moderate to severe ulcerative colitis that has a specific immune feature (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks, and researchers will check if symptoms improve. The goal …

This study tests an experimental drug called amlitelimab for adults with severe alopecia areata, a condition causing significant hair loss. About 166 participants will receive either the drug or a placebo as a shot under the skin for 36 weeks. The goal is to see if the drug can s…

This study tests an experimental drug called BIVV020 in 48 adults who have received or will receive a kidney transplant. The goal is to see if it can prevent or treat antibody-mediated rejection, a common complication where the body attacks the new kidney. Participants receive BI…

This study tests whether a daily pill called venglustat can work as well as or better than standard enzyme infusions (Cerezyme) for people with Gaucher disease type 3. About 43 adults and teens who have been stable on enzyme therapy for at least 3 years will take either the pill …

This large Phase 3 study compares a new investigational drug, frexalimab, to an approved daily pill (teriflunomide) in about 1655 adults with relapsing forms of multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants…

This study tests a new drug called brivekimig in people recently diagnosed with type 1 diabetes. The goal is to see if it can help preserve the body's ability to make some insulin, reducing the need for injected insulin. About 84 adults and adolescents will receive either the dru…

This phase 3 study tests whether the experimental drug venglustat can reduce heart muscle thickening (left ventricular hypertrophy) in adults with Fabry disease better than current standard treatments. About 104 participants will receive either venglustat or usual care (agalsidas…

This study looks at the long-term safety and effectiveness of a drug called amlitelimab for adults with moderate-to-severe asthma. Participants had already completed a previous amlitelimab study and will continue receiving the drug for up to 144 weeks. The goal is to see if the d…

This phase 3 study tests whether the drug frexalimab can delay worsening disability in people with a form of multiple sclerosis called nonrelapsing secondary progressive MS (nrSPMS). About 943 adults aged 18 to 60 are receiving either frexalimab or a placebo for up to 36 months. …

This study tests an experimental drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis. Participants receive either one of three doses of the drug or a placebo for up to 52 weeks. The goal is to see if the drug can reduce symptoms and inflammation, and to…

This study is testing a new drug called SAR447537 (INBRX-101) for adults with a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) that causes lung damage (emphysema). The goal is to see if the drug is safe and effective over the long term by monitoring side effe…

This study tests a pre-mixed injection that combines two diabetes drugs (insulin glargine and lixisenatide) in adults with type 2 diabetes whose blood sugar is not well controlled by pills or other injectables. About 105 participants will receive the combo treatment to see if it …

This study tests a one-time gene therapy (SAR444836) for adults with phenylketonuria (PKU), a genetic disorder that makes it hard to break down an amino acid called phenylalanine (Phe). The goal is to lower Phe levels in the blood and allow participants to eat a normal diet witho…

This study tests the drug dupilumab in adults with eosinophilic esophagitis (EoE), a condition that makes swallowing difficult. Participants receive either dupilumab or a placebo for 24 weeks, then all receive dupilumab for 2 more years. The goal is to see if the drug improves es…

This study tests whether dupilumab, an add-on treatment, can slow the loss of lung function in adults with moderate to severe asthma that is not well controlled by standard inhalers. About 1,339 participants will receive either dupilumab or a placebo for 3 years, while continuing…

This study looks at the long-term safety of a drug called itepekimab for adults with chronic sinusitis and nasal polyps that are hard to control. Participants who finished a previous itepekimab study can join and will receive either a high or low dose of the drug for up to 52 wee…

This phase 3 study tests whether adding isatuximab to standard therapy (lenalidomide and dexamethasone) can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combination or the two-d…

This study looks at the long-term safety of the drug tolebrutinib in adults with multiple sclerosis (MS). It includes 2,500 people who have already taken part in earlier trials of this drug. Researchers will track side effects and check if the drug continues to help control the d…

This study tests a new enzyme replacement therapy called avalglucosidase alfa in infants with Pompe disease, a rare genetic disorder that causes severe muscle weakness. The treatment is given by IV every other week for up to 4 years. The main goal is to see if more babies survive…

This study offers continued access to the drug isatuximab for adults with multiple myeloma who are still benefiting from it after finishing an earlier clinical trial. The main goal is to monitor long-term safety. About 70 participants will receive the treatment and be watched for…

This phase 3 study tests whether giving the drug isatuximab as a shot under the skin works as well as giving it through an IV for people with multiple myeloma that has come back or not responded to treatment. About 531 adults who have already tried at least one prior therapy will…

This study tests an experimental drug called amlitelimab in adults with nonresponsive celiac disease—people who still have symptoms and gut damage despite following a strict gluten-free diet. About 229 participants will receive either the drug or a placebo as a shot under the ski…

This study looks at the long-term safety of a gene therapy called SAR421869 in 9 people with Usher syndrome type 1B, a rare genetic disorder that causes vision and hearing loss. Participants received the treatment in an earlier study and are now being followed to see if it remain…

This study tests whether adding the drug belumosudil to standard steroids helps control chronic graft-versus-host disease (cGVHD) better than steroids alone. cGVHD is a long-term complication after a stem cell transplant where the donor cells attack the patient's body. The trial …

This study tests a monthly injection called fitusiran in 91 males aged 12 and older with severe hemophilia A or B, including those with inhibitors. The goal is to see if fitusiran reduces the number of bleeding episodes compared to their usual treatment. Participants first receiv…

This study tests a new way to give the drug isatuximab under the skin (instead of through a vein) for people with multiple myeloma that has come back or stopped responding to treatment. About 118 adults who have already tried 1 to 3 other treatments will receive isatuximab along …

This early-stage study tests a new drug, SAR442257, in about 47 adults with multiple myeloma or non-Hodgkin lymphoma that returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for early signs …

This study follows about 200 people with hemophilia A who are already using efanesoctocog alfa as part of their routine care. Researchers will track joint bleeding and joint health over up to 5 years to see how well the treatment works in real life. No experimental drugs are give…

This study tests whether a monthly injection of amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. About 1,500 participants who already responded to the drug in earlier studies will either continue trea…

This study tests whether adding the drug isatuximab to a standard three-drug combination (bortezomib, lenalidomide, and dexamethasone) helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The trial includes about 475 adults aged 65 or…

This study looks at how well dupilumab (Dupixent) works over 2 years in children aged 6 to 14 with moderate-to-severe atopic dermatitis (eczema). About 48 kids will receive the drug and have their skin barrier function measured. The goal is to see if long-term treatment improves …

This study tests the safety of a 14-day treatment with teplizumab in 20 children under 8 years old who have early-stage (Stage 2) type 1 diabetes. The goal is to see if the drug is safe and how the body processes it. Teplizumab aims to slow down the disease and delay the need for…

This study looks at the long-term safety and effectiveness of amlitelimab, an injected drug for moderate to severe eczema (atopic dermatitis). It includes over 1,600 people who have already taken amlitelimab in earlier studies. Some participants will stop treatment temporarily to…

This study tests an experimental drug called SAR441344 in people with active systemic lupus erythematosus (SLE). The goal is to see if it can reduce lupus symptoms and disease activity better than a placebo. About 109 adults aged 18 to 70 will receive either the drug or a placebo…

This study offers continued treatment with the oral drug rilzabrutinib to adults with chronic immune thrombocytopenia (ITP) who have already completed a long-term extension study in Japan. Only 4 participants who showed meaningful benefit and acceptable safety are eligible. The m…

This study aims to understand the long-term safety and effectiveness of the drug riliprubart for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that damages nerves and causes weakness. It is an extension study for up to 300 people who have alrea…

This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and toddlers up to 24 months old. About 110 children will receive the medicine as part of their regular care. Researchers will track any side effects and how many children get sick with RS…

This study follows 100 adults with prurigo nodularis whose doctors have already decided to treat them with dupilumab. Researchers will observe how the drug is used in real life, including dosing changes and reasons for stopping. The goal is to understand long-term effectiveness a…

This study tests if dupilumab injections can reduce severe itching in adults with lichen simplex chronicus, a condition causing thick, itchy skin patches. About 142 participants will receive either dupilumab or a placebo for 24 weeks. The main goal is to see if more people get me…

This study tests if dupilumab, given as injections, can reduce severe itching in adults with lichen simplex chronicus, a skin condition causing intense scratching. About 138 participants will receive either dupilumab or a placebo for 24 weeks, and researchers will measure itch im…

This study tests whether the drug venglustat can reduce nerve pain in the arms and legs, and belly pain, in people with Fabry disease. About 122 participants aged 16 and older who have not been treated for Fabry in the last 6 months will take either venglustat or a placebo for 12…

This study tests an experimental drug called itepekimab in 60 adults with chronic sinusitis that doesn't improve with standard sprays. The goal is to see if it reduces sinus swelling and symptoms like stuffiness, runny nose, and facial pain. Participants receive either the drug o…

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) in Spain who are starting treatment with dupilumab. Researchers will observe how the medicine is used in real-world clinics and track its effectiveness and safety over two years. No e…

This study looks at whether healthcare professionals in Saudi Arabia are aware of and follow safety measures for the drug Leflunomide (ARAVA), used for rheumatoid and psoriatic arthritis. Researchers will survey about 3,500 doctors and pharmacists to see if they received and read…

This study follows 150 adults in France with severe chronic sinusitis and nasal polyps who are taking dupilumab (Dupixent). Researchers will describe patient characteristics, past treatments, and how symptoms change over two years. The goal is to understand real-world use and saf…

This study follows 376 asthma patients aged 12 and older who are starting Dupixent in real-world clinics. Researchers will collect information on patients' medical history, how they use the drug, and how well it controls their asthma. The goal is to understand typical patient pro…